[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659665":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":44,"studyPopulation":33,"armGroups":45,"interventions":58,"overallOfficials":33,"centralContacts":67,"locations":33,"responsibleParty":73,"collaborators":33,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":33,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":100,"whyStopped":33,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":33},{"fullName":5,"class":6},"Vida Recoletas Sevilla","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":33},[9],{"measure":10,"description":11,"timeFrame":12},"Clinical pregnancy rate per embryo transfer","Proportion of embryo transfers resulting in an intrauterine gestational sac and fetal heartbeat confirmed by ultrasound.","6-9 weeks of gestation after embryo transfer.",[14,18,21,25,29],{"measure":15,"description":16,"timeFrame":17},"Biochemical pregnancy rate per embryo transfer","Proportion of participants with a positive serum β-hCG test after embryo transfer.","9-15 days after embryo transfer.",{"measure":19,"description":20,"timeFrame":12},"Ongoing pregnancy rate per embryo transfer","Proportion of participants with embryonic heartbeat detected.",{"measure":22,"description":23,"timeFrame":24},"Live birth rate per embryo transfer","Proportion of participants with a live-born infant at delivery.","From embryo transfer through delivery, up to 9 months after embryo transfer.",{"measure":26,"description":27,"timeFrame":28},"Biochemical pregnancy loss rate per embryo transfer","Pregnancy loss after a positive or indeterminate β-hCG result, without ultrasound confirmation of a gestational sac.","From serum β-hCG testing at 9-15 days after embryo transfer through ultrasound assessment at 6-9 weeks of gestation.",{"measure":30,"description":31,"timeFrame":32},"Clinical pregnancy loss rate per embryo transfer","Pregnancy loss after an intrauterine gestational sac has been confirmed.","After ultrasound confirmation of the gestational sac; the protocol does not specify a final follow-up time point.",null,{"allocation":35,"interventionModel":36,"interventionModelDescription":37,"primaryPurpose":38,"observationalModel":33,"timePerspective":33,"maskingInfo":39},"RANDOMIZED","PARALLEL","Randomized trial with two parallel groups and 1:1 allocation according to the embryo transfer medium.","TREATMENT",{"masking":40,"maskingDescription":33,"whoMasked":41},"DOUBLE",[42,43],"PARTICIPANT","CARE_PROVIDER","Hyaluronic acid is commonly used in embryo transfer media to support embryo-endometrial adhesion. GM-CSF is a cytokine that may help regulate cellular stress and apoptosis after embryo warming. This study will compare a GM-CSF-supplemented transfer medium with a hyaluronic acid-supplemented medium in frozen embryo transfer cycles. Its primary aim is to determine whether the GM-CSF medium is non-inferior to the hyaluronic acid medium for clinical pregnancy. The results may help inform the choice of transfer medium in assisted reproduction.",[46,52],{"label":47,"type":48,"description":49,"interventionNames":50},"GM-CSF-supplemented transfer medium","EXPERIMENTAL","Participants receive a single frozen embryo transfer using SAGE 1-Step medium with GM-CSF.",[51],"Other: Cytokine-rich embryo transfer medium",{"label":53,"type":54,"description":55,"interventionNames":56},"Hyaluronic acid-enriched transfer medium","ACTIVE_COMPARATOR","Participants receive a single frozen embryo transfer using EmbryoGlue medium enriched with hyaluronic acid.",[57],"Other: Hyaluronic acid-enriched embryo transfer medium",[59,63],{"type":6,"name":60,"description":61,"armGroupLabels":62,"otherNames":33},"Cytokine-rich embryo transfer medium","Embryo transfer medium enriched with cytokines, used for the transfer of cryopreserved embryos.",[47],{"type":6,"name":64,"description":65,"armGroupLabels":66,"otherNames":33},"Hyaluronic acid-enriched embryo transfer medium","Embryo transfer medium enriched with hyaluronic acid, used for the transfer of cryopreserved embryos.",[53],[68],{"name":69,"role":70,"phone":71,"phoneExt":33,"email":72},"Nicolás Prados Dodd","CONTACT","+34 954 28 62 74","vida.investiga@gruporecoletas.com",{"type":74,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100659665","cryopreserved-pre-embryo-transfer-in-a-cytokine-rich-medium-versus-hyaluronic-acid-100659665",false,"NCT07869576","Cryopreserved Pre-embryo Transfer in a Cytokine-rich Medium Versus Hyaluronic Acid","Transferencia de Preembriones Criopreservados en un Medio Rico en Citoquinas Versus ácido hialurónico: Estudio clínico Aleatorizado","CSF-EG","Inclusion Criteria:\n\n* Women aged 18 to 50 years.\n* Undergoing transfer of a single cryopreserved embryo (SET) from own and\u002For donor gametes.\n\nExclusion Criteria:\n\n* Uterine malformations or conditions that, in the physician's judgment, could affect implantation.\n* Transfer of more than one embryo.\n* Transfer of mosaic embryos.","FEMALE","18 Years","50 Years",{"count":87,"type":88},610,"ESTIMATED","INTERVENTIONAL",[91],"NA","This multicenter, randomized, double-blind study compares a GM-CSF-enriched embryo transfer medium with a hyaluronic acid-enriched medium in women undergoing single frozen embryo transfer. It will assess whether the GM-CSF medium is non-inferior for clinical pregnancy rates. Participants will be randomly assigned to one of the two groups.",[94],"Frozen Embryo Transfer (FET)",[96,97,98,99],"frozen embryo transfer","GM-CSF","hyaluronic acid","culture media","NOT_YET_RECRUITING","2026-10-06",{"date":103,"type":104},"2026-10-09","ACTUAL",{"date":106,"type":88},"2026-10",{"date":108,"type":88},"2028-10",{"name":5,"class":6}]